Clinical significance of plasma lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA) in gynaecologic cancer patients.
A comparison between plasma lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA) in gynaecologic cancer patients has been performed. The LBSA level appears more specific then the CEA, especially for ovarian cancer. This finding has promoted a longitudinal study to show if LBSA test may prove a reliable marker of disease in ovarian cancer patients.
D001943:Breast Neoplasms / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood*; D006801:Humans; D008055:Lipids / Q000097:blood*; D019158:N-Acetylneuraminic Acid; D010051:Ovarian Neoplasms / Q000097:blood; D012794:Sialic Acids / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000097:blood; D014594:Uterine Neoplasms / Q000097:blood
D002272:Carcinoembryonic Antigen; D008055:Lipids; D012794:Sialic Acids; D019158:N-Acetylneuraminic Acid